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Purpose or Objective: Anal cancers are treated by definitive 
chemoradiotherapy of the primary tumor and pelvic nodes. 
Although survival is high (5y 75%), locoregional recurrence 
occurs in 24% of patients. Patients are mostly treated with 
IMRT and VMAT, and therefore precise dose delivery is 
important. For target volume delineation typically either PET 
or MRI is used together with planning CT, but practice varies 
between institutions. In the current work, we aim to 
investigate the variability between imaging modalities and 
oncologists with respect to target volume delineation based 
on either PET/CT or MRI/CT information. 
 
Material and Methods: Twenty patients with anal cancer 
referred to chemoradiotherapy were prospectively included. 
Written informed consent was obtained from all patients and 
the regional ethics committee approved the study. Prior to 
therapy, patients underwent a planning CT scan, a PET/CT 
scan with 18FDG and T2 and diffusion weighted MRI scans at a 
3T scanner. At the treatment planning station (Varian 
Eclipse), all images where co-registered to the planning CT 
scan. Three oncologists delineated the Gross tumor volume 
(GTV) independently of each other twice for each patient, 
once with medical records and images blinded for MRI 
information, and once blinded for PET information. The CT 
image information was always available. A randomization 
scheme of the order of the anonymized patients was used 
during delineation to minimize intra-observer bias. All 
volumes were exported from the treatment planning system, 
analyzed by calculating the DICE coefficients and compared 
with the Wilcoxon Signed-rank test. 
 
Results: The median volume of the GTV was respectively 
27.5 cm3 and 31.0 cm3 for PET and MRI, and there was a high 
correlation (r=0.94) between the volumes. The DICE 
coefficient (minimum, median, maximum) was 0.43, 0.81, 
0.93 and 0.50, 0.75, 0.89 for PET and MRI. These DICE 
distributions were significantly different (P=0.03). Half of the 
patients with low DICE (<0.7) for PET, also gave low DICE for 
MRI, this indicated difficulties with delineation irrespective 
of imaging modality. For inter-modality comparison (PET to 
MRI for same observer), the DICE coefficient was 0.31, 0.75, 
0.92, with a significant difference in distribution relative to 
the inter-observer distribution. 
 
 
Conclusion: PET and MRI produced similar GTV volumes for 
radiotherapy planning of anal cancer. However, PET has a 
significantly lower inter-observer variability in terms of the 
DICE coefficients. Still, the deviations between PET and MRI 
were not substantial and may not translate into clinically 
meaningful differences. This is also supported by the 
relatively high inter-modality DICE coefficients. Thus, 
radiotherapy target delineation for anal cancer is performed 
quite consistently among observers and is not strongly 
dependent on whether PET or MRI is used. 
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Purpose or Objective: In locally advanced rectal cancer 
(LARC), further advances in individualised treatment 
approaches require identification of robust biomarkers. 
Although metabolic reprogramming has been regarded 
essential for cancer cell proliferation, the systematic 
characterisation of activated metabolic pathways in 
aggressive cancer is scarce. Hence, by recognising the link 
between altered tumour metabolism and disease 
aggressiveness, we aimed to identify associations between 
pretreatment tumour metabolic profiles and therapeutic 
outcome in LARC. 
 
Material and Methods: Tumour metabolic profiles were 
acquired from 54 LARC patients, receiving induction 
neoadjuvant chemotherapy followed by long-course 
chemoradiotherapy and surgery, by using high-resolution 
magic angle spinning magnetic resonance spectroscopy. 
Metabolite concentrations were correlated to TNM and 
presence of disseminated tumour cells (DTC) at time of 
diagnosis, and to ypTN and tumour regression grade (TRG) 
following the neodjuvant treatment. All patients had either 
reached 5 years of follow-up or were scored with a 
progression-free survival (PFS) event at time of analysis. The 
performance of metabolite concentrations in prediction of 
PFS was assessed by receiver operating characteristic curves. 
Univariate Cox regression assessed associations between 
selected variables and PFS; those being significant were 
entered into multivariate analysis. Survival differences were 
assessed by the Kaplan-Meier method. 
 
Results: Pretreatment tumour metabolite concentrations 
showed no significant associations to TNM, DTC, ypTN or TRG. 
In univariate regression analysis, high concentrations of 
glycine, creatine and myo-inositol were significantly 
associated to poor PFS, with distant metastasis to the lung 
and/or liver being the main PFS event (87.5% of events). 
When separating patients above and below the identified cut-
off concentrations the respective estimated 5-year PFS were 
85% and 50% for glycine, 74% and 29% for creatine and 81% 
and 50% for myo-inositol. In multivariate analysis, high 
glycine concentration remained most significantly associated 
to poor PFS (hazard ratio = 4.4, 95% confidence interval = 
1.4–14.3, p = 0.008). 
 
Conclusion: High tumour glycine concentration was 
identified as adverse prognostic factor for PFS in LARC. In a 
patient population treated with curative intent but with 
metastatic disease as main PFS event these results motivate 
further investigations of glycine as early predictor of 
metastatic progression and as potential therapeutic target. 
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